RARE Stock Analysis: Buy, Sell, or Hold?
RARE - Ultragenyx Pharmaceutical Inc.
$24.07
-0.20 (-0.82%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 12, 2026
12d
Get Alerted When RARE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RARE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RARE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RARE is currently trading at $24.07, which is considered fair relative to its 30-day fair value range of $20.98 to $29.06.
Technical Outlook: Technically, RARE is in a downtrend. Immediate support is located at $22.00, while resistance sits at $25.00.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $64.00 (+163.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RARE is in a downtrend. Immediate support is located at $22.00, while resistance sits at $25.00.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $64.00 (+163.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$20.98 -
$29.06
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 163.7% below Wall St target ($64.00)
Fair Price Analysis
30-Day Fair Range
$20.98 -
$29.06
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$22.00
Resistance Level
$25.00
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-5.68
Wall Street Target
$64.00
(+163.7%)
Revenue Growth (YoY)
14.7%
Profit Margin
-92.0%
Last updated: January 30, 2026 4:12 PM ET
Data refreshes hourly during market hours. Next update: 5:12 PM
Data refreshes hourly during market hours. Next update: 5:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RARE showing a specific setup today?
Insider Activity (6 Months)
1
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Howard Horn
SELL
7942 shares
2025-10-13
Theodore Alan Huizenga
SELL
64 shares
2025-09-18
Karah Herdman Parschauer
SELL
2450 shares
2025-09-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$85 | 55 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 63 BUY |
Advanced RARE Option Strategies
Professional options setups generated by AI based on today's RARE price and gamma walls.
